Security key
034569103
Anebulo Pharmaceuticals, Inc. - Common Stock (ANEB)
CUSIP: 034569103
Q3 2023 13F Holders as of 30 Sep 2023
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 41,587,315
- Total 13F shares
- 7,050,491
- Share change
- +16,949
- Total reported value
- $21,560,562
- Price per share
- $3.06
- Number of holders
- 11
- Value change
- +$51,779
- Number of buys
- 4
- Number of sells
- 2
Report period
Q3 2023
Institutions
11
Top holders
10
ANEB full security history
Newer quarter: Q4 2023
Previous quarter: Q2 2023
Anebulo Pharmaceuticals, Inc. SEC filings
Anebulo Pharmaceuticals, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 034569103
Recent filing periods:
Top shareholders of ANEB - Anebulo Pharmaceuticals, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| 22NW, LP |
13F
|
Company |
12%
|
5,066,290
|
$11,905,782 | — | 30 Jun 2023 | |
| LVW Advisors, LLC |
13F
|
Company |
1.6%
|
672,331
|
$1,579,978 | — | 30 Jun 2023 | |
| Nantahala Capital Management, LLC |
13F
|
Company |
1.2%
|
511,073
|
$1,201,022 | — | 30 Jun 2023 | |
| MANGROVE PARTNERS IM, LLC |
13F
|
Company |
0.96%
|
399,219
|
$938,165 | — | 30 Jun 2023 | |
| Praetorian PR LLC |
13F
|
Company |
0.43%
|
180,005
|
$423,012 | — | 30 Jun 2023 | |
| Ikarian Capital, LLC |
13F
|
Company |
0.38%
|
156,203
|
$340,523 | — | 30 Jun 2023 | |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
|
Company |
0.04%
|
17,319
|
$40,700 | — | 30 Jun 2023 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.04%
|
16,032
|
$37,675 | — | 30 Jun 2023 | |
| BlackRock Finance, Inc. |
13F
|
Company |
0.02%
|
7,253
|
$17,045 | — | 30 Jun 2023 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.01%
|
6,101
|
$14,337 | — | 30 Jun 2023 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
57
|
$134 | — | 30 Jun 2023 | |
| Simon Allen |
3/4/5
|
Chief Executive Officer, Director |
—
class O/S missing
|
70,246
|
— | — | 09 Dec 2022 | |
| Karah Herdman Parschauer |
3/4/5
|
Director |
—
class O/S missing
|
30,425
|
— | — | 21 Apr 2022 |
Institutional Holders of Anebulo Pharmaceuticals, Inc. - Common Stock (ANEB) as of Q3 2023
As of 30 Sep 2023,
Anebulo Pharmaceuticals, Inc. - Common Stock (ANEB) was held by
11 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
7,050,491 shares.
The largest 10 holders included
22NW, LP, LVW Advisors, LLC, Nantahala Capital Management, LLC, MANGROVE PARTNERS, Praetorian PR LLC, Ikarian Capital, LLC, VANGUARD GROUP INC, Tower Research Capital LLC (TRC), BOOTHBAY FUND MANAGEMENT, LLC, and BlackRock Inc..
This page lists
11
institutional shareholders reporting positions in this security
for the Q3 2023 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2023 vs Q2 2023 Across Filers
Q2 2023 holders
11
Q3 2023 holders
11
Holder diff
0
| Investor | Q2 2023 Shares | Q3 2023 Shares | Share Diff | Share Chg % | Q2 2023 Value $ | Q3 2023 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.